遠隔モニタリング プラットフォーム「CUREETY TECHCARE」と一次治療を開始する mTBNC 患者向けの標準治療 (ALTERNATIVE)
第一選択の全身治療を開始するトリプルネガティブ転移性乳がん患者を対象に、デジタル遠隔モニタリングプラットフォーム「CUREETY TECHCARE」と通常の標準治療を比較するランダム化第III相試験
The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.
The main questions it aims to answer are:
- Is patient quality of life improved by using the telemonitoring platform?
- Are patients hospitalized less frequently when using the telemonitoring platform?
- Is the patient overall survival improved by telemonitoring ?
Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.
Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Arras、フランス
- Institut de Cancérologie des Hauts-de-France (ICHF)
-
Auxerre、フランス
- Centre Hospitalier d'Auxerre
-
Avignon、フランス
- Sainte Catherine - Institut du Cancer Avignon Provence
-
Bayeux、フランス
- CH Aunay-Bayeux
-
Beauvais、フランス
- Centre Hospitalier Simone Veil de Beauvais
-
Beuvry、フランス
- ICHF - Centre Pierre Curie
-
Blois、フランス
- Hôpital Simone Veil de Blois
-
Bordeaux、フランス
- Polyclinique bordeaux nord
-
Bourg-en-Bresse、フランス
- Centre Hospitalier Fleyriat
-
Caen、フランス
- Centre de Cancérologie Privé de Caen Maurice Tubiana
-
Caen、フランス
- Centre Francois Baclesse
-
Carcassonne、フランス
- Centre hospitalier de Carcasonne
-
Chambray-lès-Tours、フランス
- Recherche Oncologie Clinqiue 37 (ROC 37)
-
Cholet、フランス
- CH de Cholet
-
Colmar、フランス
- CH Colmar
-
Creil、フランス
- Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
-
Dijon、フランス
- Centre Georges François Leclerc
-
Dunkirk、フランス
- Institut Andrée Dutreix
-
Fréjus、フランス
- Centre Hospitalier Intercommunal de Fréjus Saint Raphael
-
Grenoble、フランス
- Groupe Hospitalier Mutualiste de Grenoble
-
La Rochelle、フランス
- Groupe Hospitalier de La Rochelle-Ré-Aunis
-
La Réunion、フランス
- CHU de la réunion
-
La Réunion、フランス
- Clinique Sainte Clotilde
-
La Tronche、フランス
- CHU Grenoble Alpes
-
Le Coudray、フランス
- Centre Hospitalier Louis Pasteur
-
Le Mans、フランス
- Centre Hospitalier Le Mans
-
Le Puy-en-Velay、フランス
- Centre Hospitalier Emile Roux
-
Lorient、フランス
- GHBS Lorient
-
Lyon、フランス
- Clinique de la Sauvegarde
-
Lyon、フランス
- Centre Leon Berard
-
Lyon、フランス
- Hôpital Privé Jean Mermoz
-
Marseille、フランス
- Institut Paoli Calmettes
-
Mont-de-Marsan、フランス
- CHI de Mont-de-Marsan et du Pays des Sources
-
Montpellier、フランス
- Centre de Cancérologie du Grand Montpellier
-
Nantes、フランス
- Hôpital Privé du Confluent
-
Neuilly-sur-Seine、フランス
- Clinique Ambroise-Pare Hartmann
-
Neuilly-sur-Seine、フランス
- Hôpital Américain de PARIS
-
Nîmes、フランス
- CHU de Nimes
-
Orléans、フランス
- CHR Orleans
-
Osny、フランス
- CHP Sainte-Marie
-
Paris、フランス
- Diaconesses Croix Saint-Simon Hospital Complex
-
Pau、フランス
- Centre hospitalier de Pau
-
Plérin、フランス
- CARIO - Hopital Privé des Cotes d'Armor
-
Poitiers、フランス
- CHU de Poitiers
-
Reims、フランス
- Institut Godinot
-
Rouen、フランス
- Clinique Mathilde - Les Hôpitaux Privés Rouennais
-
Saint-Etienne、フランス
- CHU de Saint-Etienne
-
Saint-Mandé、フランス
- Hia Begin
-
Tours、フランス
- CHU de Tours
-
Vandœuvre-lès-Nancy、フランス
- Institut de Cancérologie de Lorraine
-
Épagny、フランス
- CH Annecy Genevois
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
- Patients ≥18 years of age.
- Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
- Life expectancy > 6 months as per investigator estimate.
- Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
- Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
- Affiliated to the social security system or equivalent health insurance.
- Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
- Patient has access to a computer, tablet, or smartphone connected to the Internet.
Exclusion Criteria:
- Participation in another clinical trial using telemonitoring.
- Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
- Patient deprived of their liberty or under protective custody or guardianship.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:標準治療グループ
|
|
|
実験的:Telemonitoring group
Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare". |
Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient). The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to definitive Health-Related Quality of life score Deterioration
時間枠:At baseline then every 3 months, up to 24 months
|
The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred. The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life. |
At baseline then every 3 months, up to 24 months
|
|
Hospitalization-free survival
時間枠:From randomization to death from any cause, up to 24 months
|
Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive. |
From randomization to death from any cause, up to 24 months
|
|
Overall survival
時間枠:From randomization to death from any cause, up to 24 months after last inclusion
|
overall survival is the length of time from randomization during which patients enrolled in the study remain alive. |
From randomization to death from any cause, up to 24 months after last inclusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time-to-treatment failure
時間枠:From randomization to treatment discontinuation, up to 24 months
|
Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation. |
From randomization to treatment discontinuation, up to 24 months
|
|
Toxicity-free survival
時間枠:From randomization until the first event, up to 24 months
|
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first. |
From randomization until the first event, up to 24 months
|
|
Time to clinical deterioration
時間枠:From randomization, to the date of the first clinical deterioration, up to 24 months
|
-Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead). |
From randomization, to the date of the first clinical deterioration, up to 24 months
|
|
Number of treatment lines
時間枠:Throughout study completion, up to 24 months
|
Number of successive treatment lines offered to the patient from randomization to the end of the study. |
Throughout study completion, up to 24 months
|
|
Incidence of Adverse Events
時間枠:Throughout study completion, up to 24 months
|
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. |
Throughout study completion, up to 24 months
|
|
Quality of life questionnaire - Core 30 (QLQ-C30)
時間枠:At baseline then every 3 weeks, up to 24 months
|
Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
At baseline then every 3 weeks, up to 24 months
|
|
Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)
時間枠:At baseline then every 3 weeks, up to 24 months
|
This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items. |
At baseline then every 3 weeks, up to 24 months
|
|
Treatment compliance and extent of exposure
時間枠:Throughout study completion, up to 24 months
|
The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions. |
Throughout study completion, up to 24 months
|
|
Compliance with the use of Cureety digital telemonitoring
時間枠:Throughout study completion, up to 24 months
|
Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires. |
Throughout study completion, up to 24 months
|
|
Satisfaction with Cureety telemonitoring
時間枠:3 months after randomisation for the patients and 1 year after the site activation for medical team
|
Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team [including nurse, clinical research associate, and investigators]) satisfied by the regular usage of the Cureety telemonitoring tool. |
3 months after randomisation for the patients and 1 year after the site activation for medical team
|
|
Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35
時間枠:6 months after randomisation
|
The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent). |
6 months after randomisation
|
|
Socio-economic impact of digital telemonitoring
時間枠:Throughout study completion, up to 24 months after randomization
|
Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations |
Throughout study completion, up to 24 months after randomization
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- UC-BCG-2309
- IDRCB NUMBER: 2023-A02477-38 (その他の識別子:CPP Sud-Méditerranée III)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。